Portfolio Companies News
December 1, 2021Adcendo Further Strengthens Managem...
Building the team with experienced biotech experts and renowned leaders in the ADC fieldUnderscores company’s commitment to progressing lead program on novel ADC target uPARAP Copenhagen, Denmark, December 1st, 2021 – Adcendo, a biotech company focused on the development of breakthrough... read more
November 30, 2021Nordic Nanovector R&D Day: Building...
Oslo, Norway, 30 November 2021 Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, will today host an R&D day starting at 14:00 CET/ 13:00 GMT/ 08:00 ET. The meeting will be held via a ... read more
November 29, 2021Carisma Therapeutics Appoints Sanfo...
PHILADELPHIA, November 29, 2021 – Carisma Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that Sanford (Sandy) Zweifach has been appointed to the chairman position for the Board of Directors.Mr. Z... read more
November 25, 2021Priothera Appoints Elisabeth Kueenb...
Dr. Kueenburg, former Clinical Development Lead at Celgene, a Bristol Myers Squibb Company, to advance clinical development of mocravimod in Acute Myeloid Leukemia patients undergoing allogeneic hematopoietic stem cell transplant. Dublin, Ireland – 25th November 2021 – Priothera&nb... read more
November 24, 2021Oncopeptides publishes Q3 2021 repo...
Back to the future STOCKHOLM — November 24, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today published the report for the third quarter 2021. Financial ove... read more
November 29, 2021Q3 2021 General Market Overview
October 07, 2021HealthCap strengthens senior team
November 29, 2021HealthCap’s 25th company anniversary!
Since the start in 1996, HealthCap funds have invested in 125 portfolio companies.
46 of the portfolio companies have been taken public on nine different markets.
29 of the portfolio companies pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 12 companies with a valuation of USD 1 billion or more.